What vaccines should be administered during pregnancy to provide passive immunity to the newborn, preventing the need for immediate post‑birth vaccinations?

Vaccines During Pregnancy That Provide Passive Immunity to Newborns

All pregnant women should receive Tdap vaccine between 27-36 weeks' gestation (preferably 27-28 weeks), influenza vaccine during any trimester, and RSV vaccine (RSVpreF) at 32-36 weeks' gestation to provide immediate passive immunity to their newborns, preventing the need for early infant vaccination against these diseases 1, 2.

Core Recommended Vaccines

Tdap (Tetanus, Diphtheria, Pertussis)

• Timing: 27-36 weeks' gestation, with optimal timing at 27-28 weeks 1, 3
• Rationale: Maternal antibodies transfer across the placenta and protect newborns from pertussis during the vulnerable first months of life before the infant vaccination series begins
• The "cocooning" strategy (vaccinating close contacts) was found to be poorly effective, making maternal vaccination the most cost-effective prevention strategy 1
• This prevents severe pertussis disease in infants, who experience the highest morbidity and mortality from this infection

Influenza Vaccine (Inactivated)

• Timing: Any trimester during pregnancy or up to 6 months postpartum if not given during pregnancy 1, 3
• Critical caveat: Only the inactivated vaccine is safe—the live attenuated intranasal vaccine is contraindicated due to theoretical risk of placental viral transmission 1
• Protection occurs through two mechanisms: transplacental IgG antibody transfer and secretory IgA antibodies in breast milk that persist up to 6 months postpartum 1
• While third-trimester vaccination produces higher cord blood antibody titers, first-trimester infection carries the greatest risk of fetal death and adverse outcomes, supporting earlier vaccination 1

RSV Vaccine (RSVpreF)

• Timing: 32-36 weeks' gestation, administered September-January in most of the continental United States 2, 3
• Key decision point: Infants need at least 14 days after maternal vaccination for adequate antibody development and transfer 2
• Important exceptions requiring infant nirsevimab instead:
  • Infants born <34 weeks' gestation (cannot receive vaccine early enough for protection)
  • Infants born <14 days after maternal vaccination (insufficient time for antibody transfer)
  • Infants born outside RSV season (April-September) who enter their first RSV season at <8 months 2

Additional Vaccines Under Specific Circumstances

COVID-19 Vaccine

• Timing: Any trimester during pregnancy 3
• Provides transplacental antibody transfer, though protection wanes after approximately 3 months 2

Hepatitis B

• Safe during pregnancy when indicated for high-risk exposure 1, 4
• Prevents vertical transmission and provides passive immunity to the newborn

Critical Contraindications

Live attenuated vaccines are absolutely contraindicated during pregnancy 4:

• MMR (measles, mumps, rubella)
• Varicella
• Live attenuated influenza (intranasal)

These should be administered during pre-pregnancy counseling with advice to avoid pregnancy for one month afterward 4.

Clinical Implementation Pitfalls

1. RSV vaccine timing confusion: The earliest an infant can be protected is if born at 34 weeks after maternal vaccination at 32 weeks. Any infant born earlier requires nirsevimab regardless of maternal vaccination status 2

2. Influenza vaccine formulation error: Ensure only inactivated vaccine is used—the intranasal formulation is contraindicated 1

3. Tdap timing optimization: While the window is 27-36 weeks, earlier administration (27-28 weeks) is preferred to maximize antibody transfer before delivery 3

4. RSV vs. nirsevimab decision: Most infants do not need both products. Maternal vaccination provides immediate protection at birth but wanes after 3 months, while nirsevimab may provide longer-lasting protection 2

Mechanism of Protection

Maternal vaccination during pregnancy works through transplacental transfer of IgG antibodies, providing passive immunity that protects newborns during their most vulnerable period before they can mount their own immune responses to infant vaccines 1, 5. The efficiency of transfer depends on gestational age, maternal immune competence, placental integrity, and timing of vaccination 5.

The evidence supporting these recommendations comes from high-quality guidelines 1, 2 with robust safety and efficacy data showing no significant increase in adverse pregnancy or neonatal outcomes 6, making maternal vaccination a critical component of prenatal care that directly reduces infant morbidity and mortality.